Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of aficamten in adults with symptomatic hypertrophic cardiomyopathy
NL-OMON59663Phase 2Recruiting
- Sponsor
- Cytokinetics
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aficamten in hypertrophic cardiomyopathy (HCM), sponsored by Cytokinetics. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 1 more. Started May 2023; status: recruiting.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NL-OMON59663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59663.